An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Solid Tumors and Hematologic Malignancy Clinical Trial

Official title:
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Status Terminated

Clinical Trial Summary

This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment groups also had an intra-patient dose titration (Part 2).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Neoplasms
Solid Tumors and Hematologic Malignancy

Clinical Trial Details

NCT number	NCT02431260
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	April 14, 2015
Completion date	January 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02492789` - A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients	Phase 1
Terminated	`NCT02712905` - An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies	Phase 1/Phase 2
Completed	`NCT01195311` - A Dose-escalation Study in Subjects With Advanced Malignancies	Phase 1
Completed	`NCT00820560` - Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors	Phase 1
Withdrawn	`NCT02355431` - Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations	Phase 2